1. Home
  2. NUWE vs AZTR Comparison

NUWE vs AZTR Comparison

Compare NUWE & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuwellis Inc.

NUWE

Nuwellis Inc.

N/A

Current Price

$1.09

Market Cap

1.7M

Sector

Health Care

ML Signal

N/A

Logo Azitra Inc

AZTR

Azitra Inc

N/A

Current Price

$0.24

Market Cap

1.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NUWE
AZTR
Founded
1999
2014
Country
United States
United States
Employees
38
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7M
1.9M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
NUWE
AZTR
Price
$1.09
$0.24
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
70.6K
21.8M
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.06
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.14
N/A
Revenue Next Year
$18.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$0.10
52 Week High
$25.95
$1.40

Technical Indicators

Market Signals
Indicator
NUWE
AZTR
Relative Strength Index (RSI) 37.37 51.60
Support Level $0.96 $0.14
Resistance Level $1.19 $0.25
Average True Range (ATR) 0.08 0.04
MACD 0.04 0.00
Stochastic Oscillator 59.93 45.05

Price Performance

Historical Comparison
NUWE
AZTR

About NUWE Nuwellis Inc.

Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: